These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 15541815

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, Han J, Park J, Kim DH.
    J Clin Oncol; 2004 Jun 15; 22(12):2363-70. PubMed ID: 15197197
    [Abstract] [Full Text] [Related]

  • 3. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH.
    Carcinogenesis; 2004 Nov 15; 25(11):2165-71. PubMed ID: 15231689
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, Lee HC, Wang YC.
    Cancer; 2007 Nov 01; 110(9):2019-26. PubMed ID: 17876837
    [Abstract] [Full Text] [Related]

  • 5. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K.
    Cancer; 2006 May 15; 106(10):2190-9. PubMed ID: 16598757
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J.
    Clin Cancer Res; 2002 Jul 15; 8(7):2362-8. PubMed ID: 12114441
    [Abstract] [Full Text] [Related]

  • 7. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF.
    Cancer; 2004 Apr 01; 100(7):1472-7. PubMed ID: 15042681
    [Abstract] [Full Text] [Related]

  • 8. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T.
    Lung Cancer; 2007 Oct 01; 58(1):131-8. PubMed ID: 17606310
    [Abstract] [Full Text] [Related]

  • 9. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A, Srinivasan R, Shabnam MS, Majumdar S, Joshi K, Behera D.
    Mol Cancer Res; 2006 Feb 01; 4(2):93-9. PubMed ID: 16513840
    [Abstract] [Full Text] [Related]

  • 10. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK.
    Clin Cancer Res; 2008 May 01; 14(9):2664-72. PubMed ID: 18451230
    [Abstract] [Full Text] [Related]

  • 11. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
    Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T, Nakajima T, Nakagawara A, Kimura H.
    Oncol Rep; 2006 May 01; 15(5):1281-5. PubMed ID: 16596198
    [Abstract] [Full Text] [Related]

  • 12. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH.
    Cancer Res; 2006 Apr 15; 66(8):4049-54. PubMed ID: 16618724
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.
    Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J.
    Cancer Res; 1998 Dec 01; 58(23):5478-83. PubMed ID: 9850082
    [Abstract] [Full Text] [Related]

  • 14. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
    Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L.
    Cancer Res; 1999 Oct 01; 59(19):4798-803. PubMed ID: 10519387
    [Abstract] [Full Text] [Related]

  • 15. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
    Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, Shim YM, Han J, Park J.
    Cancer Res; 2003 Oct 01; 63(19):6206-11. PubMed ID: 14559805
    [Abstract] [Full Text] [Related]

  • 16. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C, Tsai HY, Chen JT, Chen CY, Wang YC.
    Eur J Cancer; 2004 Sep 01; 40(14):2175-83. PubMed ID: 15341994
    [Abstract] [Full Text] [Related]

  • 17. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Harris CC.
    Cancer Res; 1998 Jun 15; 58(12):2533-6. PubMed ID: 9635574
    [Abstract] [Full Text] [Related]

  • 18. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Ito M, Ito G, Kondo M, Uchiyama M, Fukui T, Mori S, Yoshioka H, Ueda Y, Shimokata K, Sekido Y.
    Cancer Lett; 2005 Jul 08; 225(1):131-9. PubMed ID: 15922865
    [Abstract] [Full Text] [Related]

  • 19. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
    Yu ZH, Wang YC, Chen LB, Song Y, Liu C, Xia XY, Lin Q, Ma CY.
    Zhonghua Zhong Liu Za Zhi; 2008 Apr 08; 30(4):284-7. PubMed ID: 18788633
    [Abstract] [Full Text] [Related]

  • 20. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L.
    Lung Cancer; 2007 May 08; 56(2):289-94. PubMed ID: 17267069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.